Technical Analysis for LXRX - Lexicon Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 5.96 -22.60% -1.74
LXRX closed down 22.6 percent on Friday, January 18, 2019, on 7.11 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The bears made the stock sink to a new 52-week low.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical LXRX trend table...

Date Alert Name Type % Chg
Jan 18 Fell Below 20 DMA Bearish 0.00%
Jan 18 Fell Below 50 DMA Bearish 0.00%
Jan 18 MACD Bearish Centerline Cross Bearish 0.00%
Jan 18 New 52 Week Closing Low Bearish 0.00%
Jan 18 Expansion Breakdown Bearish Swing Setup 0.00%
Jan 18 Gilligan's Island Buy Setup Bullish Swing Setup 0.00%
Jan 18 Volume Surge Other 0.00%
Jan 18 New 52 Week Low Weakness 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%

Older signals for LXRX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for human disease. Its portfolio of orally-delivered small molecule compounds in clinical development include LX4211 that has completed two Phase II clinical trials for the treatment of type 1 and type 2 diabetes; LX1032, which is in Phase III clinical trials for the treatment of carcinoid syndrome and ulcerative colitis; and LX1033 that is in Phase II clinical trials for the treatment of irritable bowel syndrome. The company is also developing LX2931 that has completed Phase II clinical trials for the treatment of rheumatoid arthritis; and LX7101, which is in Phase I clinical trials for the treatment of glaucoma. It has drug discovery and development collaborations with Bristol-Myers Squibb Company; Genentech, Inc.; Schering-Plough/Organon; and Takeda Pharmaceutical Company Limited. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
Is LXRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 13.97
52 Week Low 5.29
Average Volume 579,034
200-Day Moving Average 9.7834
50-Day Moving Average 7.5306
20-Day Moving Average 6.9525
10-Day Moving Average 7.295
Average True Range 0.6132
ADX 18.69
+DI 14.9949
-DI 38.2144
Chandelier Exit (Long, 3 ATRs ) 6.2404
Chandelier Exit (Short, 3 ATRs ) 7.1296
Upper Bollinger Band 8.0109
Lower Bollinger Band 5.8941
Percent B (%b) 0.03
BandWidth 30.446602
MACD Line -0.0745
MACD Signal Line -0.0956
MACD Histogram 0.0211
Fundamentals Value
Market Cap 631.06 Million
Num Shares 106 Million
EPS -1.33
Price-to-Earnings (P/E) Ratio -4.48
Price-to-Sales 13.10
Price-to-Book 9.99
PEG Ratio -0.13
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.48
Resistance 3 (R3) 7.42 6.86 7.22
Resistance 2 (R2) 6.86 6.47 6.89 7.14
Resistance 1 (R1) 6.41 6.24 6.64 6.47 7.05
Pivot Point 5.85 5.85 5.96 5.88 5.85
Support 1 (S1) 5.40 5.46 5.63 5.46 4.87
Support 2 (S2) 4.84 5.23 4.87 4.78
Support 3 (S3) 4.39 4.84 4.70
Support 4 (S4) 4.45